McCarthy B J, Worrall D M
Department of Biochemistry, University College Dublin Belfied, Ireland.
J Mol Biol. 1997 Apr 4;267(3):561-9. doi: 10.1006/jmbi.1996.0909.
Ovalbumin is a non-inhibitory serpin which lacks the ability to undergo the S --> R transition or conformational change. Amino acid residues in the hinge region (P11 to P14) of ovalbumin and other non-inhibitory serpins differ from the concensus sequence of this region of inhibitory serpins, and have been proposed to be responsible for lack of inhibitory properties, particularly the P14 charged residue. Site directed mutagenesis using PCR overlap extension was performed on these residues in ovalbumin to create a mutant with three amino acid changes, R340T, V342A and V343A. However analysis of the mutant recombinant ovalbumin with the consensus residues failed to show inhibitory activity or decreased stability, indicating that the hinge region alone is not responsible for lack of inhibition. A series of three fusion proteins were then constructed by replacing varying C-terminal regions of ovalbumin with the corresponding region of the inhibitory ov-serpin PAI-2 in order to further analyse serpin inhibitory function. Fusion proteins F1 and F2 contained approximately 16% and 35% PAI-2, respectively. This resulted in the replacing of structural features such as the reactive site loop, hinge region and beta sheet strands 5A and 6A. However both fusion proteins showed no inhibitory activity with the PAI-2 target protease urokinase (uPA) and no decrease in stability as analysed by transverse urea gradient (TUG) gels. The third chimeric fusion protein constructed (F3) contained 64% PAI-2 and did demonstrate inhibition of uPA, SDS-PAGE stable complex formation with uPA and increased instability on TUG gels. Structural differences between the inactive F2 and active F3 include the replacement of helix F and beta sheet strand 3A of ovalbumin with those of PAI-2, suggesting that these features may have a key role in serpin beta-sheet opening and inhibitory function.
卵清蛋白是一种非抑制性丝氨酸蛋白酶抑制剂,它缺乏进行S→R转变或构象变化的能力。卵清蛋白和其他非抑制性丝氨酸蛋白酶抑制剂的铰链区(P11至P14)中的氨基酸残基与抑制性丝氨酸蛋白酶抑制剂该区域的共有序列不同,并且有人提出这是导致缺乏抑制特性的原因,特别是P14带电荷的残基。利用PCR重叠延伸技术对卵清蛋白中的这些残基进行定点诱变,以产生具有三个氨基酸变化(R340T、V342A和V343A)的突变体。然而,对具有共有残基的突变体重组卵清蛋白的分析未能显示出抑制活性或稳定性降低,这表明仅铰链区并非导致缺乏抑制作用的原因。然后构建了一系列三种融合蛋白,通过用抑制性卵清蛋白纤溶酶原激活物抑制剂-2(PAI-2)的相应区域替换卵清蛋白不同的C末端区域,以进一步分析丝氨酸蛋白酶抑制剂的抑制功能。融合蛋白F1和F2分别含有约16%和35%的PAI-2。这导致了诸如反应位点环、铰链区以及β折叠链5A和6A等结构特征的替换。然而,通过横向尿素梯度(TUG)凝胶分析,这两种融合蛋白对PAI-2靶蛋白酶尿激酶(uPA)均无抑制活性,且稳定性未降低。构建的第三种嵌合融合蛋白(F3)含有64%的PAI-2,确实表现出对uPA的抑制作用、与uPA形成SDS-PAGE稳定复合物以及在TUG凝胶上稳定性增加。无活性的F2和有活性的F3之间的结构差异包括卵清蛋白的螺旋F和β折叠链3A被PAI-2的相应结构所取代,这表明这些特征可能在丝氨酸蛋白酶抑制剂β折叠的打开和抑制功能中起关键作用。